midazolam and etravirine

midazolam has been researched along with etravirine in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Chen, FE; Clercq, E; Hao, QQ; Ling, X; Pannecouque, C1
Aharchi, F; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Leopold, L; Onkelinx, J; Peeters, M; Stevens, T; Van Solingen-Ristea, RM1

Reviews

1 review(s) available for midazolam and etravirine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for midazolam and etravirine

ArticleYear
The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.
    Journal of clinical pharmacology, 2014, Volume: 54, Issue:4

    Topics: Adolescent; Adult; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Female; Healthy Volunteers; Humans; Male; Midazolam; Middle Aged; Nitriles; Omeprazole; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Theophylline; Warfarin; Young Adult

2014

Other Studies

1 other study(ies) available for midazolam and etravirine

ArticleYear
Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
    European journal of medicinal chemistry, 2022, Aug-05, Volume: 238

    Topics: Animals; Anti-HIV Agents; HIV Reverse Transcriptase; HIV-1; Mice; Molecular Docking Simulation; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2022